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Pyoderma gangrenosum (PG) is a rare inflammatory cutaneous disorder that is thought to be due to an 
innate immune system dysfunction, specifically of neutrophils. PG has been well documented in patients 
with autoimmune disorders like Ulcerative Colitis and Rheumatoid Arthritis. PG can also present in 
surgical patients, imitating a potential wound infection and necrotizing fasciitis. Although PG is a 
diagnosis of exclusion, prompt recognition is essential to attaining desired aesthetic outcomes, especially 
with breast involvement. We present a case series of four patients who developed PG following breast 
surgery. We analyze each patient’s medical history, symptoms, wound progression and management in 
order to compare our path to diagnosis and treatment to the literature.  
  
Methods: 
The Pubmed database was strategically searched to find literature that is related to PG post breast surgery. 




Of the 4 patients, only 2 patients had a history of autoimmune disease. 3 patients underwent debridement 
of their wounds. The average time from surgery to the onset of the symptoms was 11 days. The average 
time from the onset of symptoms to the correct diagnosis of PG was 41 days. Only 2 patients were 
diagnosed by tissue biopsies; the others were diagnosed clinically after failing multiple treatments 
targeted toward postoperative cellulitis. The average length of steroid therapy was 25 days. The average 
time from the initiation of steroids to complete wound closure was 51. The average time from the onset of 
symptoms to complete wound closure bilaterally was 87 days.  
  
Discussion: 
Post surgical PG after breast surgery is a difficult diagnosis to make. It should be suspected in patients 
who develop rapidly evolving, painful, necrotic ulcers at multiple surgical sites (usually sparing the nipple 
areolar complex) that present within the first 2 weeks postoperatively and lack a response to standard 
treatments for postoperative cellulitis. Prompt treatment with systemic steroids and/or 
immunosuppressive medications should be started in order to improve outcomes and minimize morbidity. 
 
 
